Price Alert: Shares of Corcept (CORT) Trade 2.74% Higher at Midday May 13

Equities Staff  |

Today Corcept Therapeutics Inc (NASDAQ: CORT) is trading 2.74% higher.

The latest price, as of 11:52:19 est, was $19.07. Corcept has climbed $0.51 so far today.

343,735 shares have exchanged hands.

As of the previous close, Corcept has a YTD change of 5.96%. The company is set to release earnings on 2022-07-28.

For technical charts, analysis, and more on Corcept visit the company profile.

About Corcept Therapeutics Inc

Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym® was the first drug approved by the U.S. Food and Drug Administration for patients with Cushing's syndrome. Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol. The company owns extensive United States and foreign intellectual property covering the composition of its selective cortisol modulators and the use of cortisol modulators to treat a variety of serious disorders.

To get more information on Corcept Therapeutics Inc and to follow the company's latest updates, you can visit the company's profile page here: Corcept Therapeutics Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

Cisco Down 12% in Premarket Trading Thursday After Top Line Miss and Lower Forecast
Under Armour CEO Patrik Frisk To Step Down in Surprise Announcement
Target Hits 52-Week Low After Missing Badly on First Quarter Earnings
DLocal Posts Record Q1, Fifth Consecutive 100%+ Revenue Growth Quarter
Another Crypto Winter Wipes Out Billions in Market Value
Inflation + Recession = Recipe for Volatility
Twitter Down 13% in Premarket Trading Friday as Musk Puts Deal on Hold
The Best Laid Plans of Mice and Men — Part I



Market Movers

Sponsored Financial Content